Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Bremelanotide (Vyleesi) vs Insulin Lispro (Humalog)
An educational, source-based comparison of Bremelanotide (Vyleesi) and Insulin Lispro (Humalog) — how each peptide works, what it's researched for, and what to know before going deeper.
Melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women.
Cyclic 7-amino-acid synthetic analog of α-MSH that activates melanocortin receptors (primarily MC4R) in the CNS, modulating sexual desire pathways.
- Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women
- • FDA-approved.
- • Nausea, flushing, transient BP elevation common.
Recombinant insulin analog with reversed lysine and proline at B28/B29, reducing self-association so it acts within ~15 minutes for postprandial glucose control.
- Prandial coverage in T1D/T2D
- Insulin pump therapy
- Hyperglycemic crises (with caution)
- • FDA-approved.
- • Hypoglycemia risk if meal delayed or skipped.
Bremelanotide (Vyleesi) vs Insulin Lispro (Humalog) — Key differences
- Class: Bremelanotide (Vyleesi) is classified as Melanocortin Agonist · Sexual Health, while Insulin Lispro (Humalog) is Insulin Analog · Endocrine.
- Primary research focus: Bremelanotide (Vyleesi) — acquired, generalized hypoactive sexual desire disorder (hsdd) in premenopausal women; Insulin Lispro (Humalog) — prandial coverage in t1d/t2d.
- Tag: FDA-Approved · Sexual Health vs FDA-Approved · Diabetes.